Can incorporating genotyping data into efficacy estimators improve efficiency of early phase malaria vaccine trials?

ABSTRACT: Background Early phase malaria vaccine field trials typically measure malaria infection by PCR or thick blood smear microscopy performed on serially sampled blood. Vaccine efficacy (VE) is the proportion reduction in an endpoint due to vaccination and is often calculated as VE _HR =1 - hazard ratio or VE _RR = 1 - risk ratio. Genotyping information can distinguish different clones and distinguish multiple infections over time, potentially increasing statistical power. This paper investigates two alternative VE endpoints incorporating genotyping information: VE _molFOI , the vaccine-induced proportion reduction in incidence of new clones acquired over time, and VE _C , the vaccine-induced proportion reduction in mean number of infecting clones per exp

SUBMITTER: Potter GE 

PROVIDER: S-EPMC10543529 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature